Post-Bariatric Hypoglycemia Market Set for 16.4% CAGR Through 2036 as Novel Therapies Advance

At present, PBH management primarily relies on dietary interventions and off-label pharmacological approaches because there is no FDA-approved medication specifically indicated for the condition. Dietary modification remains an important component of care and generally involves frequent meals with lower glycemic loads and increased protein and fiber intake.

Acarbose is commonly used as an initial pharmacological option, although gastrointestinal adverse effects may restrict its tolerability and long-term use. Other agents, including diazoxide, calcium channel blockers, and somatostatin analogues such as octreotide, have been explored with varying degrees of success. However, inconsistent efficacy, tolerability concerns, side effects, and adherence challenges continue to limit their broader use.

These limitations have created a considerable treatment gap and strengthened the rationale for developing therapies that directly target the mechanisms involved in PBH.

Novel Drug Classes Could Reshape the PBH Market

One of the most significant developments in the emerging PBH treatment landscape is the advancement of mechanism-based drug classes. GLP-1 receptor antagonists have attracted considerable attention because excessive GLP-1 signaling is believed to contribute to the exaggerated insulin response observed after meals in many patients with PBH.

Avexitide, developed by Amylyx Pharmaceuticals, is among the most advanced candidates in this category. The therapy, also known as exendin 9-39, is a 31-amino-acid peptide that selectively blocks GLP-1 receptors. By reducing inappropriate insulin secretion, avexitide is designed to decrease both fasting and postprandial hypoglycemic episodes. It has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S. FDA for hyperinsulinemic hypoglycemia.

Another GLP-1 receptor antagonist under development is Imapextide (MBX 1416), developed by MBX Biosciences. The long-acting peptide is designed to provide sustained GLP-1 receptor blockade while potentially reducing dosing frequency. Its development could offer an additional treatment option for patients experiencing recurrent PBH episodes.

Beyond GLP-1 receptor antagonism, SGLT1 inhibition represents another promising approach. Vogenx’s Mizagliflozin is an orally administered, minimally absorbed SGLT1 inhibitor designed to slow intestinal glucose absorption. By reducing rapid glucose uptake after meals, the therapy aims to moderate postprandial glucose excursions and excessive insulin release. Mizagliflozin is currently being investigated in a Phase IIb clinical trial.

Competitive Pipeline Continues to Expand

The PBH pipeline is becoming more diversified as companies investigate different biological pathways. Recordati Group is developing Pasireotide (SIGNIFOR), while Confo Therapeutics is advancing CFTX-2034. AMX0318 is being developed through collaboration involving Amylyx Pharmaceuticals and Gubra, while Hanmi is advancing Efpegerglucagon.

The presence of candidates targeting different mechanisms could potentially improve treatment personalization in the future. However, the majority of investigational programs remain in relatively early stages of development, and many clinical studies have involved limited patient populations. Consequently, additional evidence will be required to determine the durability of treatment effects, long-term safety, and effectiveness across diverse patient groups.

Avexitide currently stands out because of its advanced clinical development stage and the absence of an approved pharmacological treatment specifically for PBH. If successful in late-stage trials and subsequent regulatory review, it could potentially establish a new benchmark for PBH management.